Lyra Therapeutics (LYRA) Competitors $0.18 -0.02 (-10.10%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends LYRA vs. PAVM, TTOO, PYPD, STIM, DRIO, NXL, CLGN, MLSS, BLAC, and COCHShould you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include PAVmed (PAVM), T2 Biosystems (TTOO), PolyPid (PYPD), Neuronetics (STIM), DarioHealth (DRIO), Nexalin Technology (NXL), CollPlant Biotechnologies (CLGN), Milestone Scientific (MLSS), Bellevue Life Sciences Acquisition (BLAC), and Envoy Medical (COCH). These companies are all part of the "medical equipment" industry. Lyra Therapeutics vs. PAVmed T2 Biosystems PolyPid Neuronetics DarioHealth Nexalin Technology CollPlant Biotechnologies Milestone Scientific Bellevue Life Sciences Acquisition Envoy Medical PAVmed (NASDAQ:PAVM) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, profitability, risk and institutional ownership. Do analysts rate PAVM or LYRA? PAVmed currently has a consensus target price of $21.00, suggesting a potential upside of 1,938.83%. Lyra Therapeutics has a consensus target price of $4.50, suggesting a potential upside of 2,428.09%. Given Lyra Therapeutics' higher possible upside, analysts clearly believe Lyra Therapeutics is more favorable than PAVmed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PAVmed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Lyra Therapeutics 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, PAVM or LYRA? PAVmed has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500. Is PAVM or LYRA more profitable? PAVmed has a net margin of 602.97% compared to Lyra Therapeutics' net margin of -6,635.76%. PAVmed's return on equity of 0.00% beat Lyra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PAVmed602.97% N/A -92.36% Lyra Therapeutics -6,635.76%-125.07%-59.74% Does the MarketBeat Community believe in PAVM or LYRA? PAVmed received 178 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. Likewise, 66.01% of users gave PAVmed an outperform vote while only 60.00% of users gave Lyra Therapeutics an outperform vote. CompanyUnderperformOutperformPAVmedOutperform Votes20266.01% Underperform Votes10433.99% Lyra TherapeuticsOutperform Votes2460.00% Underperform Votes1640.00% Which has higher earnings and valuation, PAVM or LYRA? Lyra Therapeutics has lower revenue, but higher earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPAVmed$2.45M4.65-$64.18M-$4.35-0.24Lyra Therapeutics$1.56M7.47-$62.68M-$1.49-0.12 Do institutionals & insiders believe in PAVM or LYRA? 19.9% of PAVmed shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 14.7% of PAVmed shares are owned by company insiders. Comparatively, 4.7% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media refer more to PAVM or LYRA? In the previous week, Lyra Therapeutics had 1 more articles in the media than PAVmed. MarketBeat recorded 10 mentions for Lyra Therapeutics and 9 mentions for PAVmed. Lyra Therapeutics' average media sentiment score of 0.65 beat PAVmed's score of 0.24 indicating that Lyra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PAVmed 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Lyra Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPAVmed and Lyra Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Lyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LYRA vs. The Competition Export to ExcelMetricLyra TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.65M$4.42B$5.06B$8.82BDividend YieldN/A41.17%5.18%4.07%P/E Ratio-0.1224.81126.3217.81Price / Sales7.4747.011,179.2574.56Price / CashN/A51.8733.8632.53Price / Book0.114.974.684.68Net Income-$62.68M$13.76M$119.54M$226.08M7 Day Performance-1.11%-1.08%-1.83%-1.04%1 Month Performance-27.05%0.58%-3.60%1.04%1 Year Performance-94.29%50.91%31.91%26.28% Lyra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LYRALyra Therapeutics3.3293 of 5 stars$0.18-10.1%$4.50+2,428.1%-94.1%$12.81M$1.56M-0.1250Analyst RevisionNews CoverageHigh Trading VolumePAVMPAVmed3.9879 of 5 stars$1.03+1.0%$21.00+1,938.8%-68.7%$11.29M$2.45M0.0090Gap DownTTOOT2 Biosystems2.4481 of 5 stars$0.46-4.2%$5.00+982.7%-88.3%$10.16M$7.19M0.00180PYPDPolyPid2.8587 of 5 stars$3.49-3.1%$12.00+243.8%-14.3%$17.27MN/A0.0080Positive NewsHigh Trading VolumeSTIMNeuronetics2.796 of 5 stars$0.80+6.6%$4.67+481.5%-40.6%$22.92M$71.35M0.00180DRIODarioHealth1.8622 of 5 stars$0.78-1.3%$4.00+412.8%-31.6%$26.94M$20.35M0.00200NXLNexalin Technology0.7353 of 5 stars$3.80-2.1%$3.00-21.1%+1,051.5%$49.90M$110,000.000.003CLGNCollPlant Biotechnologies1.8582 of 5 stars$4.23+1.0%$11.00+160.0%-24.2%$48.43M$10.96M-2.7570Upcoming EarningsMLSSMilestone Scientific2.1701 of 5 stars$0.68+9.7%$1.25+84.4%-15.8%$48.30M$9.83M0.0030Analyst ForecastBLACBellevue Life Sciences AcquisitionN/A$11.60-0.6%N/A+11.0%$46.86MN/A0.00N/ACOCHEnvoy Medical3.0553 of 5 stars$2.15+5.4%$7.92+268.2%+115.0%$42.14M$320,000.000.0034Gap Up Related Companies and Tools Related Companies PAVM Competitors TTOO Competitors PYPD Competitors STIM Competitors DRIO Competitors NXL Competitors CLGN Competitors MLSS Competitors BLAC Competitors COCH Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LYRA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LYRA Stock Alerts